News

Onxeo Ordinary and Extraordinary General Meeting on April 6, 2016 // DANISH TRANSLATION: Onxeo ordinær og ekstraordinær generalforsamling den 6. april 2016

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) –  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that Onxeo’s shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which is being held on April 6, 2016 at 10.00 AM CET at Onxeo’s headquarters:…read more →

Onxeo announces acquisition of DNA Therapeutics and provides update on Validive® development plan // DANISH TRANSLATION: Onxeo offentliggør opkøb af DNA Therapeutics og giver en opdatering om udviklingsplanen for Validive®

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo acquires first-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment  Acquisition expands Company’s R&D pipeline and opens new opportunities in orphan oncology indications Further development of Validive® to be conducted in partnership Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company…read more →

Onxeo Reports 2015 Full-Year Results and Provides Business Update // DANISH TRANSLATION: Onxeo offentliggør resultat for helåret 2015 og opdaterer om virksomheden

NB! FOR DANISH TRANSLATION, SCROLL DOWN. 2015: Successful year of consolidation and major achievements in all lead programs Progression of Phase III trial of Livatag® in HCC in line with development calendar; positive results of Phase I trial of Beleodaq® and CHOP in 1st-line PTCL New preclinical development program of lead products in combination with immunotherapy and other cancer agents…read more →

Onxeo expands collaborations to advance development program of key orphan oncology assets in combination with immuno-oncology agents // DANISH TRANSLATION: Onxeo udvider sine samarbejdsaftaler for at videreudvikle sit program med væsentlige aktiver inden for sjældne kræftsygdomme i kombination med immune-onkologiske stoffer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Following first positive results already obtained  in several types of tumors  New partnership with CIMA’s Immunology Program and the Liver Unit at Clinica Universidad de Navarra in Spain under the leadership of Prof. B. Sangro Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan…read more →

Onxeo to attend upcoming investor conferences and medical meetings // DANISH TRANSLATION: Onxeo deltager i kommende investormøder og videnskabelige konferencer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that senior management will present updates on the Company’s advanced orphan oncology pipeline at the following upcoming investor conferences: ODDO Biotech / Medtech Forum – March 31, 2016 in Paris…read more →

Onxeo announces the evolution and reinforcement of its Board of Directors // DANISH TRANSLATION: Onxeo udvider og styrker bestyrelsen

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Drs. Jean-Pierre Kinet of Harvard Medical School, and Jean-Pierre Bizzari, international expert in Oncology, join the Onxeo Board of Directors as Board Observers Joseph Zakrzewski elected as Onxeo Chairman Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced that…read more →

Publication of shareholders’ letter // DANISH TRANSLATION: Offentliggørelse af nyhedsbrev til aktionærerne

Paris (France), Copenhagen (Denmark)– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of its 8th Shareholders Letter. This latest Shareholders Letter provides an update on Onxeo’s major achievements in 2015 with a focus on the positive results of the Phase I clinical trial of Bel-CHOP (association…read more →

Onxeo announces its financial calendar for 2016 // DANISH TRANSLATION: Onxeo offentliggør selskabets finanskalendar for 2016

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces its financial calendar for 2016: February 26, 2016                               Full-year 2015 results  April 6, 2016                                         General shareholders’ meeting (to be convened in Paris) April 28, 2016                                      Quarterly information as of March 31, 2016 July…read more →

Spectrum Pharmaceuticals and Onxeo announce complete response in 67% of patients with peripheral T-cell lymphoma in combination of belinostat (Beleodaq®) and standard CHOP // DANISH TRANSLATION: Onxeo og Spectrum Pharmaceuticals offentliggør, at der er opnået komplet respons hos 67 % af patienterne med perifert T-celle lymfekræft (PTCL) med kombinationen af belinostat (Beleodaq®) og standard CHOP-behandling

Data was Highlighted in an Oral Presentation of a Phase 1 Study at the 57th Annual Meeting of the American Society of Hematology (ASH) Study Shows 86% Objective Response Rate with 67% Complete Responses in Newly Diagnosed Patients with Peripheral T-cell Lymphoma (PTCL) At Full Dose Intensity the Belinostat-CHOP Combination was Well-Tolerated HENDERSON, Nev. and PARIS (France), COPENHAGEN (Denmark) –…read more →

Onxeo initiates comprehensive strategy to extend value of key orphan oncology assets // DANISH TRANSLATION: Onxeo indleder omfattende strategiplan for at øge værdien af selskabets vigtigste lægemidler til behandling af sjældne kræftsygdomme

Currently exploring combinations for synergistic effect to identify new indications for Livatag® and Beleodaq® Signed two collaborations with Lyon’s University Hospital and Synovo’s immuno-oncology specialists  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced the initiation of a comprehensive strategy to explore further potential indications…read more →

Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma (PTCL) — Onxeo rapporterer foreløbige resultater fra fase I-studiet til evaluering af belinostat i kombination med CHOP-behandling mod perifert T-celle lymfekræft (PTCL)

Full results to be reported in Oral Presentation at 2015 ASH (American Society of Hematology) Annual Meeting Data demonstrate 89% objective response rate, 72% complete response rate, and good safety profile of belinostat in combination with CHOP Study supports the interest of belinostat in combination with CHOP as first-line treatment for PTCL Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext…read more →

Onxeo to attend upcoming investor events — Onxeo deltager i kommende investormøder

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces its participation to financial conferences in the coming months. During these conferences, Onxeo’s management will present the recent achievements and the growth strategy of the Company to institutional and individual investors. Meetings with institutional investors:…read more →

Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive® for Treatment of Severe Oral Mucositis — Onxeo offentliggør data, der viser et højt niveau af ordinationsoverholdelse og en god sikkerhedsprofil for Validive® til behandling af svær oral mucositis

Results Presented in Oral ePoster Presentation at ASTRO Annual Meeting 2015 Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced compliance and patient acceptability results from a global Phase 2 clinical trial demonstrating daily treatment application of Validive® (Clonidine Lauriad®), a mucoadhesive buccal tablet for…read more →

Onxeo Validive® Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 — Abstract for Onxeo Validive® accepteret til mundtlig præsentation ved ASTRO’s årsmøde 2015

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that an abstract supporting the clinical evaluation of Validive® (Clonidine Lauriad®), a mucoadhesive buccal tablet developed for the prevention and treatment of chemo-radioation therapy-induced severe oral mucositis (SOM) in patients with head and neck cancer,…read more →